All In Biotech

Drug Trial Radar · NCT00004832

Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome

Last checked: Nov 20, 2026Latest source record: Mar 25, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

26

Actual

Start

Aug 1994

Primary completion

Not stated

Study completion Jun 1998

Sponsor

Sponsor type
Federal agency
Collaborators
Duke University
First posted
Feb 25, 2000

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

OBJECTIVES: I. Evaluate the safety and effectiveness of 3,4-diaminopyridine (DAP) in the treatment of patients with Lambert-Eaton myasthenic syndrome (LEMS). II. Determine the side-effects and benefits associated with DAP.

Conditions

  • Lambert-Eaton Myasthenic Syndrome

Interventions

  • 3,4-diaminopyridineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.